Loading...
NPI 1437108222 · South Weymouth, MA · Mobile Radiology Clinic/Center
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Shields Imaging Of Eastern Massachusetts LLC is a mobile radiology clinic/center provider located in South Weymouth, Massachusetts. This profile covers 6 Medicare and 2 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Shields Imaging Of Eastern Massachusetts LLC |
| Address | 55 Fogg Rd |
| City | South Weymouth |
| State | MA |
| ZIP | 02190 |
| Taxonomy | Mobile Radiology Clinic/Center |
| NPI Enumerated | May 9, 2006 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $2.7M |
| Medicaid | $774.1K |
SHIELDS IMAGING OF EASTERN MASSACHUSETTS LLC is a mobile radiology clinic/center with national NPI enumeration dating to 2006-05-09, indicating roughly 20 years of billing history and sustained presence in Medicare and Medicaid markets. Its specialty code mix and revenue patterns are consistent with a mobile PET imaging operation that supplies radiopharmaceuticals and performs PET/CT studies rather than a general outpatient imaging center.
Medicare revenue totals $2.7M while Medicaid revenue is $774.1K, so Medicare represents the larger share of lifetime government payor receipts; the provider therefore operates with a clear Medicare-majority billing profile rather than being single-payer dependent. Both payers show concentrated use of PET-related services, but the absolute scale of Medicare revenue is materially higher than Medicaid for this entity.
Revenue concentration on Medicare is extreme: the precomputed top 3 Medicare codes account for 91.1% of the provider's total Medicare revenue, indicating the practice’s Medicare business is heavily dependent on a very small set of high-value procedures (notably PET/CT and radiopharmaceutical administrations). For Medicaid the top 3 codes account for 100.0% of Medicaid revenue, signaling near-complete concentration of Medicaid billing in the same PET-related services.
The provider is a national outlier on several Medicare codes: 78815 ranks #28 of 6566 providers nationally at the 100th percentile and is labeled an extreme outlier, showing this provider performs exceptionally high volumes of PET/CT studies relative to peers. A9595 ranks #8 of 528 providers (99th percentile) and A9552 ranks #17 of 2411 providers (99th percentile); both are characterized as notably above typical national volume or extreme outliers, confirming a dominant position in specific radiopharmaceutical services on the Medicare side.
State-level Medicaid data show concentrated PET activity but more typical competitive standing: 78815 accounts for $584.3K (75.4% of Medicaid revenue) and ranks #13 of 49 in-state (75th percentile), while A9552 contributes $190.4K (24.6% of Medicaid revenue) and ranks #9 of 33 (75th percentile). These ranks indicate the provider is a meaningful in-state PET provider but not the singular dominant supplier in Massachusetts Medicaid for these codes.
The code-level mix — heavy volumes of 78815, A9595, and A9552 across payers — indicates the operation combines imaging and specialty radiopharmaceutical supply (including piflufolastat f-18 and FDG f-18) with PET/CT studies as the core service line. This suggests its business model centers on on-site PET/CT imaging complemented by administration of diagnostic radiotracers rather than broad outpatient imaging services.
Payment levels per claim vary by code and payer but the largest Medicare revenue contributors also show high average paid/claim values (for example Medicare average paid/claim figures reported with the top codes), reinforcing that high-revenue PET studies and radiopharmaceutical administrations drive the provider’s financial profile. Combined with the concentration metrics, the provider’s earnings are sensitive to utilization or reimbursement changes for a small set of PET-related codes.
Given the concentrated code mix and national-level outlier ranks for key PET and radiotracer codes, the provider’s competitive vulnerability is concentrated: any shifts in PET usage patterns, radiopharmaceutical adoption, or payer reimbursement policy for 78815, A9595, or A9552 would likely have outsized impact on revenue. Conversely, their high ranks on Medicare for these codes suggest they are a go-to provider for these services in their market and may have operational scale or niche positioning in mobile PET services.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
6 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 78815 | PET and CT scans are both standard imaging tools that allow doctors to evaluate the location and metabolic actions of tumors or cancer inside the body before beginning an active treatment regimen.… | 960 | $1,390 | $1.3M |
| A9595 | Piflufolastat f-18, diagnostic, 1 millicurie | 1,700 | $480 | $821.6K |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 870 | $410 | $357.6K |
| 78816 | The patient is injected with a radiopharmaceutical tracer called FDG (fluoro–deoxyglucose, a radioactive substance containing glucose) about one hour before the imaging is scheduled to begin. The… | 120 | $1,400 | $168K |
| A9587 | Gallium ga-68, dotatate, diagnostic, 0.1 millicurie | 1,350 | $40 | $59.4K |
| 78608 | In this diagnostic procedure, the provider performs PET, positron emission tomography, a type of nuclear imaging test. It tells how the brain is functioning with information on metabolism, such as… | 10 | $1,220 | $15.8K |
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 6 CPT/HCPCS codes.
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
2 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 78815 | PET and CT scans are both standard imaging tools that allow doctors to evaluate the location and metabolic actions of tumors or cancer inside the body before beginning an active treatment regimen.… | 1,430 | $410 | $584.3K |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 1,360 | $140 | $190.4K |
How this provider's Medicaid billing volume and revenue compare to other Massachusetts providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Massachusetts median
2 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 78815 | PET and CT scans are both standard imaging tools that allow doctors to evaluate the location and metabolic actions of tumors or cancer inside the body before beginning an active treatment regimen.… | 13 | 50 | 630 | $460 | $459.9K |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 9 | 30 | 710 | $70 | $70.5K |
Other providers in the same ZIP code as Shields Imaging Of Eastern Massachusetts LLC, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| South Shore Hospital Inc. | MA | General Acute Care Hospital | $0 | $95.1M |
| Coastal Medical Associates | MA | Anesthesiology Physician | $0 | $10M |
| Jennifer Byer | MA | Medical Oncology Physician | $3.5M | $0 |
| Harbor Medical Associates, Inc. | MA | Clinical Medical Laboratory | $1.8M | $420.7K |
| New England Eye Surgical Center Inc | MA | Ophthalmologic Surgery Clinic/Center | $1.8M | $271.1K |
| Harbor Medical Associates, Inc. | MA | Diagnostic Radiology Physician | $753K | $191K |
| Weymouth Endoscopy, LLC | MA | Endoscopy Clinic/Center | $844.3K | $4.7K |
| Patricia Hopkins | MA | Internal Medicine Physician | $733.6K | $0 |
| George Kroumpouzos | MA | Dermatology Physician | $721.7K | $0 |
| Harbor Medical Associates, Inc. | MA | Diagnostic Radiology Physician | $620.5K | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.